Breast Cancer Management Pathways during the COVID-19 pandemic: Outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Rajiv Dave*, Baek Kim, Alona Courtney, Rachel O'Connell, Tim Rattay, Vicky Taxiarchi, Jamie Kirkham, Elizabeth Camacho, Patricia Fairbrother, Nisha Sharma, Christopher Cartiledge, Kieran Horgan, Stuart McIntosh, Daniel Leff, Raghavan Vidya, Shelley Potter, Chris Holcombe, Ellen Copson, Charlotte Coles, Ramsey CutressAshu Gandhi, Cliona Kirwan

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review


The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and potential impact of these treatment decisions.

This was a national cohort study of patients with early BC undergoing multi-disciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the pre-operative, operative, and post-operative setting.

Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n=951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n=299). Where adjuvant chemotherapy was omitted (n=81), median benefit was only 3% (IQR 2%-9%) using ‘NHS Predict’. There was rapid adoption of new evidence-based hypofractionated radiotherapy (n=781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.

The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, outwith this study, the potential impact of delays to BC presentation or diagnosis remains unknown.
Original languageEnglish
JournalBritish Journal of Cancer
Publication statusAccepted/In press - 1 Dec 2020

Cite this